Alpha-甲基-1-哌啶乙醇 | 934-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: Alpha-甲基-1-哌啶乙醇
• 中文别名: α-甲基-1-哌啶乙醇；甲基-1-吡啶乙醇
• 英文名称: 1-(piperidin-1-yl)propan-2-ol
• 英文别名: N-2-hydroxypropyl piperidine；1-(piperidine-1-yl)propan-2-ol；α-methyl-1-piperidineethanol；1-piperidin-1-ylpropan-2-ol
• CAS: 934-90-7
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: UCASFSAKVJTSET-UHFFFAOYSA-N

物化性质

• 沸点：
  261.35°C (rough estimate)
• 密度：
  0.9300

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  1760
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C，惰性气体

SDS

Name:	Alpha-Methyl-1-Piperidineethanol 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	934-90-7

Section 1 - Chemical Product MSDS Name:Alpha-Methyl-1-Piperidineethanol 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
934-90-7	Alpha-Methyl-1-Piperidineethanol	97	213-295-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 934-90-7: Personal Protective Equipment Eyes: Wear safety glasses and chemical goggles if splashing is possible.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: clear orange-yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 191-194 deg C @ 760.00mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: .9300g/cm3
Molecular Formula: C8H17NO
Molecular Weight: 143.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 934-90-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Alpha-Methyl-1-Piperidineethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 934-90-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 934-90-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 934-90-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Alpha-甲基-1-哌啶乙醇 在 氯化亚砜 、 氯仿 作用下， 生成 N-(2-氯丙基)哌啶
  参考文献：
  名称：

  Synthetic Mydriatics. II

  摘要：

  DOI：

  10.1021/ja01254a053
• 作为产物：
  描述：

  1-哌啶-1-乙酮 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 Alpha-甲基-1-哌啶乙醇
  参考文献：
  名称：

  Kubota, Kumamoto Medical Journal, 1959, vol. 12, p. 308,310

  摘要：

  DOI：

文献信息

• INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20200055874A1

  公开（公告）日：2020-02-20

  Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

  Sultam化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与KEAP1-Nrf2相互作用相关的疾病状态、疾病和病况的方法，如炎症性肠病，包括克罗恩病和溃疡性结肠炎。
• Combined Ruthenium(II) and Lipase Catalysis for Efficient Dynamic Kinetic Resolution of Secondary Alcohols. Insight into the Racemization Mechanism
  作者：Belén Martín-Matute、Michaela Edin、Krisztián Bogár、F. Betül Kaynak、Jan-E. Bäckvall

  DOI：10.1021/ja051576x

  日期：2005.6.1

  Pentaphenylcyclopentadienyl ruthenium complexes (3) are excellent catalysts for the racemization of secondary alcohols at ambient temperature. The combination of this process with enzymatic resolution of the alcohols results in a highly efficient synthesis of enantiomerically pure acetates at room temperature with short reaction times for most substrates. This new reaction was applied to a wide range

  五苯基环戊二烯基钌配合物 (3) 是室温下仲醇外消旋化的极好催化剂。该过程与醇的酶促拆分相结合，可以在室温下高效合成对映异构纯的乙酸酯，大多数底​​物的反应时间都很短。这种新反应适用于包括杂芳族醇在内的多种官能化醇，对于后者中的许多醇，首次通过动态动力学拆分 (DKR) 有效制备了对映纯乙酸酯。制备并研究了不同取代的环戊二烯基钌配合物作为醇外消旋化的催化剂。发现五芳基取代的环戊二烯基配合物是外消旋化的高效催化剂。用烷基取代芳基之一大大减慢了外消旋化过程。氢化钌 eta(5)-Ph(5)CpRu(CO)(2)H (8) 催化 (S)-1-苯基乙醇外消旋化的研究表明外消旋化发生在钌的配位范围内催化剂。在对甲苯基甲基酮（1 当量）存在下进行的 (S)-1-苯基乙醇外消旋化中缺乏酮交换支持这一结论，这产生 <1% 的 1-(对甲苯基)乙醇. 氯化钌和碘化物配合物 3a 和 3c 以及氢化钌配合物 8
• KRAS G12C INHIBITORS
  申请人：Mirati Therapeutics, Inc.

  公开号：US20190144444A1

  公开（公告）日：2019-05-16

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别地，本发明涉及不可逆抑制KRas G12C活性的化合物、包含这些化合物的药物组合物及其使用方法。
• Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-<i>f</i>][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors
  作者：Robert M. Borzilleri、Xiaoping Zheng、Ligang Qian、Christopher Ellis、Zhen-wei Cai、Barri S. Wautlet、Steve Mortillo、Robert Jeyaseelan,、Daniel W. Kukral、Aberra Fura、Amrita Kamath、Viral Vyas、John S. Tokarski、Joel C. Barrish、John T. Hunt、Louis J. Lombardo、Joseph Fargnoli、Rajeev S. Bhide

  DOI：10.1021/jm0501275

  日期：2005.6.1

  A series of substituted 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines was identified as potent and selective inhibitors of the tyrosine kinase activity of the growth factor receptors VEGFR-2 (Flk-1, KDR) and FGFR-1. The enzyme kinetics associated with the VEGFR-2 inhibition of compound 50 (K(i) = 52 +/- 3 nM) confirmed that the pyrrolo[2,1-f][1,2,4]triazine analogues

  一系列取代的4-（2,4-二氟-5-（甲氧基氨基甲酰基）苯基氨基）吡咯并[2,1-f] [1,2,4]三嗪被确定为有效的和选择性的酪氨酸激酶活性抑制剂。生长因子受体VEGFR-2（Flk-1，KDR）和FGFR-1。与VEGFR-2抑制化合物50有关的酶动力学（K（i）= 52 +/- 3 nM）证实吡咯并[2,1-f] [1,2,4]三嗪类似物与ATP具有竞争性。几种类似物表现出对VEGF和FGF依赖的人脐静脉内皮细胞（HUVEC）增殖的低纳摩尔抑制作用。吡咯并[2,1-f] [1,2,4]三嗪核心的C6酯取代基被杂环生物等排体取代，例如取代的1,3,5-恶二唑，所提供的化合物在小鼠中具有优异的口服生物利用度（即50 F（po）= 79％）。用化合物44、49和50对植入无胸腺小鼠中的已建立的L2987人肺癌异种移植物观察到显着的抗肿瘤功效。介绍了该系列中类似物的合成，构效关系，药理学和药代动力学特性的完整说明。
• Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040209865A1

  公开（公告）日：2004-10-21

  The present invention relates to alkyne compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1 . The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔烃化合物 1 其中基团和残基A、B、W、X、Y、Z、R 1 和R 2 具有权利要求中给出的含义。本发明还涉及含有根据本发明至少一种炔烃的药物组合物。鉴于它们的MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食紊乱，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。

表征谱图